FDA Grants Accelerated Approval to Zanubrutinib (Brukinsa) for Relapsed or Refractory Follicular Lymphoma Lymphoma 2 Mins Read32 On March 7, 2024, the Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib, marketed as Brukinsa by BeiGene…
